Mohammad Rahmati-Yamchi1, Nosratollah Zarghami2, Hojjatollah Nozad Charoudeh3, Yasin Ahmadi1, Behzad Baradaran4, Mohammad Khalaj-Kondori5, Morteza Milani6, Abolfazl Akbarzadeh6, Maghsud Shaker2, Mohammad Pourhassan-Moghaddam7. 1. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.; Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 2. Department of Clinical Biochemistry, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. 3. Stem Cell Research center, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 5. Department of Biology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran. 6. Liver and Gastrointestinal disease research center, Tabriz University of Medical Sciences, Tabriz, Iran. 7. Department of Medical biotechnology, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
PURPOSE: Clofarabine, a purine nucleoside analogue and inhibitor of Ribonucleotide Reductase (RR), is used for treatment of leukemia. Clofarabine-induced defect in DNA replication, induces p53 and subsequently P53R2 genes as subunit of RR. clofarabine deregulated P53R2 gene expression leading to the elevated levels of P53R2 which impose resistance to DNA damaging drugs. In this study the apoptotic and cytotoxic effects of clofarabine has been investigated on breast cancer cell line. METHODS: Cofarabine cytotoxicity on T47D cells has been studied by MTT assay. T47D cells were exposed to the different concentrations of clofarabine for 24, 48 and 72 hours intervals. Relative expression of P53R2 gene has been studied using real-time PCR. Moreover, after treating with clofarabine the apoptotic and necrotic cells were detected using Annexin V and propodium iodide (PI) reagents by flowcytometry technique. RESULTS: MTT assay results showed that the clofarabine IC50 on T47D cell line were 3 and 2.5µM after 48 and 72 h exposure, respectively. Clofarabine did not show any significant cytotoxic effect after 24 h exposure. The analysis of qRT-PCR showed a significant increase in P53R2 gene expression in treated cells with both 2.5 and 3 μM doses and also, the results of flowcytometry revealed 26.91 and 74.46 percent apoptosis induction in 48 and 72h treatments respectively in comparison to the control groups. CONCLUSION: Our results showed that apoptotic and cytotoxic effects of clofarabine on T47D cell line were in time and dose dependent manner; therefore it could be considered a new candidate in breast cancer therapy.
PURPOSE:Clofarabine, a purine nucleoside analogue and inhibitor of Ribonucleotide Reductase (RR), is used for treatment of leukemia. Clofarabine-induced defect in DNA replication, induces p53 and subsequently P53R2 genes as subunit of RR. clofarabine deregulated P53R2 gene expression leading to the elevated levels of P53R2 which impose resistance to DNA damaging drugs. In this study the apoptotic and cytotoxic effects of clofarabine has been investigated on breast cancer cell line. METHODS:Cofarabinecytotoxicity on T47D cells has been studied by MTT assay. T47D cells were exposed to the different concentrations of clofarabine for 24, 48 and 72 hours intervals. Relative expression of P53R2 gene has been studied using real-time PCR. Moreover, after treating with clofarabine the apoptotic and necrotic cells were detected using Annexin V and propodium iodide (PI) reagents by flowcytometry technique. RESULTS:MTT assay results showed that the clofarabine IC50 on T47D cell line were 3 and 2.5µM after 48 and 72 h exposure, respectively. Clofarabine did not show any significant cytotoxic effect after 24 h exposure. The analysis of qRT-PCR showed a significant increase in P53R2 gene expression in treated cells with both 2.5 and 3 μM doses and also, the results of flowcytometry revealed 26.91 and 74.46 percent apoptosis induction in 48 and 72h treatments respectively in comparison to the control groups. CONCLUSION: Our results showed that apoptotic and cytotoxic effects of clofarabine on T47D cell line were in time and dose dependent manner; therefore it could be considered a new candidate in breast cancer therapy.
Entities:
Keywords:
Apoptosis; Breast Cancer; DNA damage; P53R2
Authors: Sima Jeha; Paul S Gaynon; Bassem I Razzouk; Janet Franklin; Richard Kadota; Violet Shen; Lori Luchtman-Jones; Michael Rytting; Lisa R Bomgaars; Susan Rheingold; Kim Ritchey; Edythe Albano; Robert J Arceci; Stewart Goldman; Timothy Griffin; Arnold Altman; Bruce Gordon; Laurel Steinherz; Steven Weitman; Peter Steinherz Journal: J Clin Oncol Date: 2006-04-20 Impact factor: 44.544
Authors: Shinjiro Nagai; Kazumasa Takenaka; Deepa Nachagari; Charles Rose; Kali Domoney; Daxi Sun; Alex Sparreboom; John D Schuetz Journal: Cancer Res Date: 2011-01-18 Impact factor: 12.701
Authors: Giovanna Pontarin; Paola Ferraro; Leonardo Bee; Peter Reichard; Vera Bianchi Journal: Proc Natl Acad Sci U S A Date: 2012-07-30 Impact factor: 11.205
Authors: Hagop M Kantarjian; Varsha Gandhi; Peter Kozuch; Stefan Faderl; Francis Giles; Jorge Cortes; Susan O'Brien; Nuhad Ibrahim; Fadlo Khuri; Min Du; Mary Beth Rios; Sima Jeha; Peter McLaughlin; William Plunkett; Michael Keating Journal: J Clin Oncol Date: 2003-03-15 Impact factor: 44.544